Renin-angiotensin system inhibitors and angioedema: Anesthetic implications

Current Opinion in Anaesthesiology

Volumn 25, Issue 3, 2012, Pages 356-362

  Stojiljkovic, Ljuba ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

airway edema; angioedema; angiotensin converting enzyme inhibitors; bradykinin; renin angiotensin system

Indexed keywords

AMINOPEPTIDASE P; ANTIHISTAMINIC AGENT; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; ICATIBANT; MEMBRANE METALLOENDOPEPTIDASE; STEROID;

AFRICAN AMERICAN; ANESTHESIA; ANGIONEUROTIC EDEMA; DIABETES MELLITUS; DISEASE COURSE; DNA POLYMORPHISM; FACE; HEREDITY; HUMAN; INTUBATION; KALLIKREIN KININ SYSTEM; LARYNX; LIP; PHARYNX; PRIORITY JOURNAL; RECIPIENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING;

ANESTHESIA; ANGIOEDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; ENZYME INHIBITORS; HUMANS; INTUBATION, INTRATRACHEAL; KALLIKREIN-KININ SYSTEM; LARYNGOSCOPY; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84861101864     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328352dda5     Document Type: Review

References (62)

1. Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Curr Pharm Des 2007;13:1335-1345.
2. Audit INP. Top Therapeutic Classes by Prescriptions. Internet: IMS HEALTH a healthcare information company; 2011 [cited 20 November 2011]; http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/2010-Top-Therapeutic-Classes-by-RX.pdf.
3. Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy 2010;40:50-61. A detailed review of pathophysiology, epidemiologic data, and clinical presentation of ACEI-induced angioedema.
4. FDA. http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm. 2011. [Accessed 12 October 2011].
5. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-921.
6. Sica DA, Black HR. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? ? J Clin Hypertens 2002;4:375-380.
7. Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. Hypertension 2009;54:468-470.
8. Korniyenko A, Alviar CL, Cordova JP, Messerli FH. Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. Cleve Clin J Med 2011;78:297-304.
9. Saxena S, Gierl B, Eibling DE. Supraglottic swelling may not correlate with tongue swelling in angiotensin converting enzyme inhibitor-induced angioedema. Laryngoscope 2010;120:62-64.
10. Korniyenko A, Alviar CL, Cordova JP, Messerli FH. Role of angiotensinconverting enzyme inhibitors in visceral angioedema. Int J Cardiol 2011;148:377-379.
11. Oudit G, Girgrah N, Allard J. ACE inhibitor-induced angioedema of the intestine: case report, incidence, pathophysiology, diagnosis and management. Can J Gastroenterol 2001;15:827-832.
12. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004;164:910-913.
13. Herkner H, Temmel AF, Mullner M, et al. Different patterns of angioedema in patients with and without angiotensin-converting enzyme inhibitor therapy. Wien Klin Wochenschr 2001;113(5-6):167-171.
14. Hornig B, Kohler C, Schlink D, et al. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2- receptordependent mechanism. Hypertension 2003;41:1092-1095.
15. Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011;29:2273-2277. This study evaluated the incidence of angioedema recurrence after the discontinuation of ACEIs. It revealed that patients are still at risk of developing angioedema several months after they discontinued ACEIs.
16. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589-599.
17. Novartis. Highlights of prescribing information. Tekturna (aliskiren fumarate). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007 [cited 12 October 2011].
18. Ali AK. Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor. Ther Clin Risk Manag 2011;7:337-344.
19. Campbell DJ. The renin-angiotensin and the kallikrein-kinin systems. Int J Biochem Cell Biol 2003;35:784-791.
20. Shen B, El-Dahr SS. Cross-talk of the renin-angiotensin and kallikrein-kinin systems. Biol Chem 2006;387:145-150.
21. Su JB. Kinins and cardiovascular diseases. Curr Pharm Des 2006;12:3423-3435.
22. Erdos EG, Tan F, Skidgel RA. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 2010;55:214-220.
23. Erdos EG, Deddish PA. The kinin system: suggestions to broaden some prevailing concepts. Int Immunopharmacol 2002;2(13-14):1741-1746.
24. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005;111:315-320.
25. Campbell DJ, Zhang Y, Kelly DJ, et al. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clin Exp Pharmacol Physiol 2011;38:623-631.
26. Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope 2001;111:1729-1731.
27. Schiller PI, Messmer SL, Haefeli WE, et al. Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. Allergy 1997;52:432-435.
28. O'Ryan F, Poor DB, Hattori M. Intraoperative angioedema induced by angiotensinconverting enzyme inhibitors: overview and case report. J Oral Maxillofac Surg 2005;63:551-556.
29. Molinaro G, Duan QL, Chagnon M, et al. Kinin-dependent hypersensitivity reactions in hemodialysis: metabolic and genetic factors. Kidney Int 2006;70:1823-1831.
30. Kharasch ED. Angiotensin-converting enzyme inhibitor-induced angioedema associated with endotracheal intubation. Anesth Analg 1992;74:602-604.
31. Ogbureke KU, Cruz C, Johnson JV, Helfrick JF. Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy. J Oral Maxillofac Surg 1996;54:917-920.
32. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine (9)-bradykinin. J Pharmacol Exp Therapeut 2002;303:232-237.
33. Campos MM, Henriques MG, Calixto JB. The role of B1 and B2 kinin receptors in oedema formation after long-term treatment with Mycobacterium bovis bacillus Calmette-Guerin (BCG). Br J Pharmacol 1997;120:502-508.
34. Ferreira PK, Campos MM, Calixto JB. The role of sensorial neuropeptides in the edematogenic responses mediated by B (1) agonist des-Arg (9)-BK in rats pretreated with LPS. Regul Pept 2000;89:29-35.
35. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002;302:839-845.
36. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-111.
37. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 2009;23:443-452.
38. FDA. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108770. htm. 2006 [cited 12 November 2011].
39. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559.
40. Program MTFSIaAER. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ Safety-RelatedDrugLabelingChanges/ucm106669.htm. FDA; 2008 [cited 12 November 2011].
41. Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009;54:516-523.
42. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008;29:295-301.
43. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-294.
44. Korom S, De Meester I, Maas E, et al. CD26 expression and enzymatic activity in recipients of kidney allografts. Transplant Proc 2002;34:1753-1754.
45. Korom S, de Meester I, Belyaev A, et al. CD26/DPP IV in experimental and clinical organ transplantation. Adv Exp Med Biol 2003;524:133-143.
46. Byrd JB, Woodard-Grice A, Stone E, et al. Association of angiotensinconverting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy 2010;65:1381-1387.
47. Duan QL, Nikpoor B, Dube MP, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet 2005;77:617-626.
48. Woodard-Grice AV, Lucisano AC, Byrd JB, et al. Sex-dependent and racedependent association of XPNPEP2 C-2399A polymorphism with angiotensinconverting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 2010;20:532-536.
49. Cilia La Corte AL, Carter AM, Rice GI, et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat 2011;32:1326-1331. This international genetic study analyzed the effect of APP enzyme gene polymorphisms in the development of ACEI-induced angioedema. In this elegant study, the authors confirmed the association of ATG haplotype located in promoter region of XPNPEP2 gene with decreased activity of APP and the increased incidence of angioedema.
50. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004;10:499-509.
51. Gainer JV, Nadeau JH, Ryder D, Brown NJ. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996;98:283-287.
52. Chiu AG, Newkirk KA, Davidson BJ, et al. Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management. Ann Otol Rhinol Laryngol 2001;110:834-840.
53. Al-Khudari S, Loochtan MJ, Peterson E, Yaremchuk KL. Management of angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope 2011;121:2327-2334. This clinical study was designed to develop and validate a clinical algorithm for the management of ACEI-induced angioedema. They found the relationship among presenting symptoms, physical exam, and fiberoptic laryngoscopic findings, which allowed for timely triage and treatment.
54. Grant NN, Deeb ZE, Chia SH. Clinical experience with angiotensin- converting enzyme inhibitor-induced angioedema. Otolaryngol Head Neck Surg 2007;137:931-935.
55. Zirkle M, Bhattacharyya N. Predictors of airway intervention in angioedema of the head and neck. Otolaryngol Head Neck Surg 2000;123:240-245.
56. Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anaesth 2006;53:994-1003.
57. Karim MY, Masood A. Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema. J Allergy Clin Immunol 2002;109:370-371.
58. Warrier MR, Copilevitz CA, Dykewicz MS, Slavin RG. Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. Ann AllergyAsthma Immunol 2004;92:573-575.
59. Shire. http://pi.shirecontent.com/PI/PDFs/Firazyr-USA-ENG.pdf. 2011 [cited 20 December 2011].
60. Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010;56:278-282. This small study confirmed a proof of concept that B2 receptor antagonist icatibant could be successfully used in the treatment of ACEI-induced angioedema.
61. Schmidt PW, Hirschl MM, Trautinger F. Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant. J Am Acad Dermatol 2010;63:913-914.
62. Munoz M, Covenas R. NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr Med Chem 2011;18:1820-1831. A review of new clinical avenues for the use of NK-1 receptor antagonists.